pipette
ESEspañol

Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections

Allan C. deCamp, Michal Juraska, Li Li, Craig A. Magaret, Brian D. Williamson, Hongjun Bai, Yunda Huang, Elena E. Giorgi, Lily Zhang, Lindsay N. Carpp, Srilatha Edupuganti, Nyaradzo Mavis Mgodi, Kevin Gillespie, Beatrix Haddock, Pedro Gonzáles, Robinson L. Cabello, Catherine Orrell, Javier R. Lama, Fatima Laher, Erica Maxine Lazarus, Jorge Sánchez, Ian Frank, Juan Hinojosa, Magdalena E. Sobieszczyk, Pamela Grace Mukwekwerere, Joseph M. Makhema, Lindsey Robert Baden, Kelly E. Seaton, John Hural, M. Juliana McElrath, Simbarashe G. Takuva, April Kaur Randhawa, Nidhi K. Kochar, Estelle Piwowar‐Manning, Deborah J Donnell, Nirupama Sista, P. Andrew, Shelly Karuna, James G. Kublin, Glenda Gray, Myron S. Cohen, Dan H. Barouch, Georgia D. Tomaras, Morgane Rolland, David C. Montefiori, Lynn Morris, James I. Mullins, Carolyn E. Williamson, Lawrence Corey, Peter B. Gilbert

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Our findings suggest that, whereas single antibodies can block sensitive strains, multiple antibodies are likely required to prevent both viral escape and breakthrough infections.

Appeared: Friday, November 6. Science Translational Medicine. Peer-reviewed journal.

DOI: 10.1126/scitranslmed.aec3480